Form 4 for NVCT Nuvectis Pharma, Inc.
Accepted 2022-02-15 00:00:00 ET · period of report 2022-02-14 · accession 0001104659-22-023547 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-02-15 | 2022-02-14 | NVCT | BENTSUR RON | COB, CEO, Dir | P - Purchase | $5.88 | +8,000 | 2.81M | +0.3% | +$47.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.00001 | 2022-02-14 | P | A | 8,000 | $5.88 | 2,814,459 | D | — | — | (F1) Reflects the weighted average purchase price. The range of prices for the shares purchased was $5.50 to $6.10. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. (F2) Includes 96,759 shares of restricted stock. |